Sep 2026· International Journal of Biological Macromolecules· Vol 382, pp.
154249
· 0 citations· 66 references
Medicine
TL;DR
It is suggested that targeting both the oxyanion hole and Leu126 may enhance both the specificity and affinity of next-generation Mac1 inhibitors.
Abstract
This study comprehensively analyzes how various inhibitors bind to the SARS-CoV-2 macrodomain Mac1, a key protein implicated in hampering the host's immune response following viral infection. In this study we used volume-based metadynamics simulations to investigate the binding mechanisms of ADP-ribose and two Mac1 inhibitors: the adenine-analogue GS-441524 and the non-adenine-analogue S09. By combining free-energy simulations with a bioinformatic analysis, we aimed at determining whether the binding patterns observed for the selected ligands can be generalized across Mac1 inhibitors and can be exploited to guide a rational design for future therapeutics. Our simulations show the pivotal role of the adenosine moiety in Mac1 recognition. However, for small molecules, like S09 and GS-441524, the oxyanion hole also emerged as an alternative and essential stabilizing region. This site, which preferentially accommodates electronegative groups, is engaged by approximately 76% of reported Mac1 inhibitors, making it a key target for Mac1 inhibition. In addition, we demonstrate that the unstructured loops 1 and 2 shape ligand entry, with loop 2 functioning as a dynamic gateway. Within this loop, Leu126, part of the virus-specific P-L-L-S motif, serves as a key anchoring residue for potent inhibitors. Collectively, these findings suggest that targeting both the oxyanion hole and Leu126 may enhance both the specificity and affinity of next-generation Mac1 inhibitors.
This work highlights how distinct inhibitors exploit different conformational states of cKIT and demonstrates the value of integrating structural analyses, biophysical measurements, calculations and molecular simulations to define the mechanism of kinase inhibition.
Irene Cipollone, Carmen Gratteri, C. Talarico et al.· International Journal of Bio...· 0 citations
The findings provide mechanistic insights into a key allosteric mechanism for Mpro inhibition but also provide a promising chemical scaffold for further development as an Mpro-targeting inhibitor.
Quanling Zhang, Tingting Wen, Meng-Si Li et al.· Drug Discoveries & Therapeut...· 0 citations
The SARS-CoV-2 main protease (Mpro) plays a crucial role in viral replication, making it an attractive target for antiviral drug development. This study evaluates the inhibitory potential of nineteen 6-substituted coumarin derivatives (1a–p and 2a–c) against Mpro using a FRET-based enzymatic assay. Among them, the chlo...
Ashraf K. El-Damasy, Md Sofequl Islam Mukim, Sangeun Jeon et al.· RSC Advances· 0 citations
The sigma-1 receptor (S1R) is a chaperone protein involved in several physiological and pathological processes and represents an attractive target for the development of neuroactive and anticancer agents. Among S1R ligands, 3,3-disubstituted 3,4-dihydro-1,2,4-benzotriazines constitute a pharmacologically relevant but m...
M. Tonelli, Valeria Francesconi, Bruno Tasso et al.· Bioorganic chemistry (Print)· 0 citations
The SARS-CoV-2 main protease (MPro) is an essential enzyme for viral replication and a primary target for antiviral drug development. Despite extensive structural and biochemical characterization, the allosteric mechanisms by which dimerization informs conformational changes at active site lack an explicit comparison a...
Javier O. Sanlley Hernandez, Carla Calvó-Tusell, Fiona L. Kearns et al.· Biophysical Journal· 0 citations
An integrated computational framework is presented that synergistically combines enhanced-sampling molecular dynamics simulations, rigorous binding free energy calculations, and quantum chemical analyses to decipher the mechanistic basis of CU-CPT22 action and establish a robust conceptual and computational framework f...
Peng Jiao, Cheng-Liang Ni, Hao Jin et al.· Journal of Molecular Graphic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.